Your SlideShare is downloading. ×
Cate buline are buburuza
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Cate buline are buburuza

583
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
583
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Presented byKirmal MasihMedicinal ChemistryMarch 25th
  • 2.  Alzheimers disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer’s is the most common form of dementia. This incurable, degenerative, terminal disease was first described by a German psychiatrist and neuropathologist Alois Alzheimer in 1906 and was named after him. Alzheimers disease (AD) is a slowly progressive disease of the brain that is characterized by impairment of memory and eventually by disturbances in reasoning, planning, language, and perception. Many scientists believe that Alzheimers disease results from an increase in the production or accumulation of a specific protein (beta-amyloid protein) in the brain that leads to nerve cell death.
  • 3.  Generally, it is diagnosed in people over 65 years of age, although the less-prevalent early onset of Alzheimer’s can occur much earlier. In 2006, there were 26.6 million sufferers worldwide. Alzheimer’s is predicted to affect 1 in 85 people globally by 2050.
  • 4. 1) Early Stage This is considered as a mild/early stage and the duration period is 2-4 years. Frequent recent memory loss, particularly of recent conversations and events. Repeated questions, some problems expressing and understanding language. Writing and using objects become difficult and depression and apathy can occur. Drastic personality changes may accompany functional decline. Need reminders for daily activities and difficulties with sequencing impact driving early in this stage.
  • 5. 2) Second stage This is considered as a middle/moderate stage and the duration is 2-10 years. Can no longer cover up problems.  Pervasive and persistent memory loss impacts life across settings. Rambling speech, unusual reasoning, confusion about current events, time, and place.  Potential to become lost in familiar settings, sleep disturbances, and mood or behavioral symptoms accelerate. Nearly 80% of patients exhibit emotional and behavioral problems which are aggravated by stress and change. Slowness, rigidity, tremors, and gait problems impact mobility and coordination.  Need structure, reminders, and assistance with activities of daily living.
  • 6. 3) Moderate stage Increased memory loss and confusion. Problems recognizing family and friends. Inability to learn new things. Difficulty carrying out tasks that involve multiple steps (such as getting dressed). Problems coping with new situations. Delusions and paranoia. Impulsive behavior. In moderate AD, damage occurs in areas of the brain that control language, reasoning, sensory processing, and conscious thought
  • 7. 4) Last stage This is considered as the severe stage and the duration is 1-3 years. Confused about past and present. Loss of recognition of familiar people and places Generally incapacitated with severe to total loss of verbal skills. Unable to care for self.  Falls possible and immobility likely. Problems with swallowing, incontinence, and illness. Extreme problems with mood, behavioral problems, hallucinations, and delirium. Patients need total support and care, and often die from infections or pneumonia
  • 8.  Alzheimers disease is usually diagnosed clinically from the patient history, collateral history from relatives, and clinical observations, based on the presence of characteristic neurological and neuropsychological features and the absence of alternative conditions. Advanced medical imaging with computed tomography (CT) or magnetic resonance imaging (MRI), and with single photon emission computer tomography (SPECT) or positron emission tomography (PET) can be used to help exclude other cerebral pathology or subtypes of dementia. The diagnosis can be confirmed with very high accuracy post-mortem when brain material is available and can be examined histologically.
  • 9. . PET scan of the brain of a person with AD showing a loss of function in the temporal lobe.
  • 10.  Neuropsychological tests such as the mini-mental state examination (MMSE) are widely used to evaluate the cognitive impairments needed for diagnosis. More comprehensive test arrays are necessary for high reliability of results, particularly in the earliest stages of the disease. Psychological tests for depression are employed, since depression can either be concurrent with AD, an early sign of cognitive impairment, or even the cause. When available as a diagnostic tool, SPECT and PET neuroimaging are used to confirm a diagnosis of Alzheimers in conjunction with evaluations involving mental status examination. In a person already having dementia, SPECT appears to be superior in differentiating Alzheimers disease from other possible causes, compared with the usual attempts employing mental testing and medical history analysis.
  • 11.  Scientists don’t yet fully understand what causes AD, but it is clear that it develops because of a complex series of events that take place in the brain over a long period of time. It is likely that the causes include genetic, environmental, and lifestyle factors.  Some drug therapies propose that AD is caused by reduced synthesis of the neurotransmitter acetylcholine.  Other cholinergic effects have also been proposed, for example, initiation of large-scale aggregation of amyloid leading to generalized neuroinflammation.  Alzheimers disease is characterized by a build-up of proteins in the brain. Though this cannot be measured in a living person, extensive autopsy studies have revealed this phenomenon. The build-up manifests in two ways: Plaques– deposits of the protein beta-amyloid that accumulate in the spaces between nerve cells Tangles – deposits of the protein tau that accumulate inside of nerve cells
  • 12. Microscopy image of a neurofibrillary tangle, conformed byhyperphosphorylated tau protein.
  • 13.  Alzheimers disease is characterised by loss of neurons and synapses in the cerebral cortex and certain subcortical regions. This loss results in gross atrophy of the affected regions, including degeneration in the temporal lobe and parietal lobe, and parts of the frontal cortex and cingulate gyrus. Both amyloid plaques and neurofibrillary tangles are clearly visible by microscopy in brains of those afflicted by AD. Plaques are dense, mostly insoluble deposits of amyloid – beta peptides and cellular material outside and around neurons. Tangles (neurofibrillary tangles) are aggregates of the microtubule-associated protein tau which has become hyperphosphorylated and accumulate inside the cells themselves. Although many older individuals develop some plaques and tangles as a consequence of ageing, the brains of AD patients have a greater number of them in specific brain regions such as the temporal lobe.
  • 14.  Alzheimers disease has been identified as a protein misfolding disease (proteopathy), caused by accumulation of abnormally folded A-beta and tau proteins in the brain. Plaques are made up of small peptides, 39–43 amino acids in length, called beta-amyloid (also written as A-beta or Aβ). Beta-amyloid is a fragment from a larger protein called amyloid precursor protein (APP), a transmembrane protein that penetrates through the neurons membrane. APP is critical to neuron growth, survival and post-injury repair. In Alzheimers disease, an unknown process causes APP to be divided into smaller fragments by enzymes through proteolysis. One of these fragments gives rise to fibrils of beta-amyloid, which form clumps that deposit outside neurons in dense formations known as senile plaques. AD is also considered a tauopathy due to abnormal aggregation of the tau protein. Every neuron has a cytoskeleton, an internal support structure partly made up of structures called microtubules. These microtubules act like tracks, guiding nutrients and molecules from the body of the cell to the ends of the axon and back. A protein called tau stabilizes the microtubules when phosphorylated, and is therefore called a microtubule- associated protein. In AD, tau undergoes chemical changes, becoming hyperphosphorylated; it then begins to pair with other threads, creating neurofibrillary tangles and disintegrating the neurons transport system.
  • 15. Enzymes act on the APP (amyloid precursor protein) andcut it into fragments. The beta-amyloid fragment is crucialin the formation of senile plaques in AD.
  • 16.  Exactly how disturbances of production and aggregation of the beta amyloid peptide gives rise to the pathology of AD is not known. The amyloid hypothesis traditionally points to the accumulation of beta amyloid peptides as the central event triggering neuron degeneration. Accumulation of aggregated amyloid fibrils, which are believed to be the toxic form of the protein responsible for disrupting the cells calcium ion homeostasis, induces programmed cell death (apoptosis). It is also known that Aβ selectively builds up in the mitochondria in the cells of Alzheimers-affected brains, and it also inhibits certain enzyme functions and the utilization of glucose by neurons. Various inflammatory processes and cytokines may also have a role in the pathology of Alzheimers disease. Inflammation is a general marker of tissue damage in any disease, and may be either secondary to tissue damage in AD or a marker of an immunological response. Alterations in the distribution of different neurotrophic factors and in the expression of their receptors such as the brain derived neurotrophic factor (BDNF) have been described in AD
  • 17.  Apolipoprotein E (APOE) found on chromosome 19 appears to be a predisposing genetic risk factor for the late on-set of AD – the most typical AD. APOE helps carry cholesterol in the bloodstream. APOE comes in several different forms, or alleles. Three forms—APOE ε2, APOE ε3, and APOE ε4 —occur most frequently.
  • 18.  Aricept Used to delay or slow the symptoms of AD Donepezil • Loses its effect over time • Used for mild, moderate and severe AD • Does not prevent or cure AD Celexa Citalopram Used to reduce depression and anxiety • May take 4 to 6 weeks to work • Sometimes used to help people get to sleep Depakote Used to treat severe aggression Sodium Valproate • Also used to treat depression and anxiety Exelon Used to delay or slow the symptoms of AD Rivastigmine • Loses its effect over time • Used for mild to moderate AD • Can get in pill form or as a skin patch • Does not prevent or cure AD
  • 19.  Namenda Used to delay or slow the symptoms of AD Memantine • Loses its effect over time • Used for moderate to severe AD • Sometimes given with Aricept®, Exelon® • Does not prevent or cure AD Razadyne Used to prevent or slow the symptoms of AD Galantamine • Loses its effect over time • Used for mild to moderate AD • Can get in pill form or as a skin patch • Does not prevent or cure AD Zoloft Used to reduce depression and anxiety Sertraline • May take 4 to 6 weeks to work • Sometimes used to help people get to sleep Trileptal Used to treat severe aggression Oxcarbazepine • Also used to treat depression and anxiety Tegretol Used to treat severe aggression Carbamazepine • Also used to treat depression and anxiety Remeron Used to reduce depression and anxiety Mirtazepine • May take 4 to 6 weeks to work • Sometimes used to help people get to sleep
  • 20.  Although there is currently no way to cure Alzheimers disease or stop its progression, researchers are making encouraging advances in Alzheimers treatment, including medications and non-drug approaches to improve symptom management. Mild/Moderate AD: Cholinesterase inhibitors increase the levels of acetylcholine in the brain, which plays a key role in memory and learning. This kind of drug postpones the worsening of symptoms for 6 to 12 months in about half of the people who take it. Cholinesterase inhibitors most commonly prescribed for mild to moderate Alzheimers disease include Aricept (donezepil HCL), Exelon (rivastigmine), and Razadyne (galantamine).
  • 21.  Moderate/Severe AD: Namenda (memantine) regulates glutamate in the brain, which plays a key role in processing information. This drug is used to treat moderate to severe Alzheimers disease and may delay the worsening of symptoms in some people. It may allow patients to maintain certain daily functions a little longer than they would without the medication.
  • 22. Razadyne Razadyne (galantamine HBr) is FDA-approved for mild and moderate stages of the disease. Razadyne is a cholinesterase inhibitor that prevents the breakdown of acetylcholine in the brain. Acetylcholine plays a key role in memory and learning; higher levels in the brain help nerve cells communicate more efficiently. Razadyne also stimulates nicotinic receptors to release more acetylcholine in the brain.
  • 23.  Razadyne delays the worsening of Alzheimers symptoms for 6 to 12 months in about half of the people who take it. Razadyne is available in tablet and capsule form, and is commonly started at 4 mg twice a day. If its well tolerated after 4 weeks, the dosage may be increased to 8 mg twice a day. Razadyne also comes in an extended release, once-a-day tablet. Razadyne is available in generic form (galantamine HBr).
  • 24. Exelon (Rivastigmine) Exelon is FDA approved for mild and moderate stages of the disease; it is also approved for the treatment of mild to moderate dementia due to Parkinsons disease. Exelon is available as a capsule, liquid, and patch.
  • 25.  Exelon is a cholinesterase inhibitor that prevents the breakdown of acetylcholine and butyrylcholine in the brain by blocking the activity of two different enzymes. Acetylcholine and butyrylcholine play a key role in memory and learning. When given orally, bioavailability is about 40% in the 3 mg dose. The compound can cross the blood-brain barrier.
  • 26. Aricept (Donepizel) One of the most widely used drugs to treat the symptoms of Alzheimers disease. Aricept is FDA-approved for mild, moderate, and severe stages of the disease.
  • 27.  Aricept is available in tablet form or an orally disintegrating tablet form, and is commonly started at 5 mg a day. Can cross the blood-brain barrier.
  • 28. Namenda (Memantine) Namenda is an N-methyl D-aspartate (NMDA) antagonist that regulates the activity of glutamate in the brain. Glutamate plays a key role in memory and learning, but excess glutamate can lead to the disruption of nerve cell communication or nerve cell death.
  • 29.  Studies involving Namenda have shown that the drug can slow the rate of decline in thinking and the ability to perform daily activities in individuals who have moderate to severe Alzheimers disease A dysfunction of glutamatergic neurotransmission is thought to be involved in the etiology of AD. Namenda is available in generic form (memantine HCL).
  • 30.  A molecule designed by a Purdue University researcher to stop the debilitating symptoms of Alzheimers disease has been shown in its first phase of clinical trials to be safe and to reduce biomarkers for the disease. The molecule, called a beta-secretase inhibitor, prevents the first step in a chain of events that leads to amyloid plaque formation in the brain. This plaque formation creates fibrous clumps of toxic proteins that are believed to cause the devastating symptoms of Alzheimers. Researchers at Mount Sinai School of Medicine have found that a compound called NIC5-15, might be a safe and effective treatment to stabilize cognitive performance in patients with mild to moderate Alzheimers disease. The two investigators, Giulio Maria Pasinetti, M.D., Ph.D. , and Hillel Grossman, M.D., presented Phase IIA preliminary clinical findings at the Alzheimers Association 2009 International Conference on Alzheimers Disease (ICAD) in Vienna on July 12.
  • 31.  NIC5-15s potential to preserve cognitive performance will be further evaluated in a Phase IIB clinical trial. Early evidence suggests that NIC5-15 is a safe and tolerable natural compound that may reduce the progression of Alzheimers disease-related dementia by preventing the formation of beta-amyloid plaque, a waxy substance that accumulates between brain cells and impacts cognitive function.
  • 32.  http://www.sciencedaily.com/releases/2008/01 /080123101629.htm http://www.sciencedaily.com/releases/2009/07 /090712145228.htm http://www.nia.nih.gov/Alzheimers/Publication s/CaringAD/other/medicines.htm http://en.wikipedia.org/wiki/Rivastigmine http://en.wikipedia.org/wiki/Galantamine http://en.wikipedia.org/wiki/Donepezil http://en.wikipedia.org/wiki/Mementine Newsweek; 06/15/98, Vol. 131 Issue 24, p52, 2p, 
  • 33.  Harvard Mental Health Letter; Apr2010, Vol. 26 Issue 10, p7-7, 1/2p Asian Journal of Animal & Veterinary Advances; 2010, Vol. 5 Issue 1, p13-23, 11p, 1 Chart, 2 Graphs Medical Device Daily; 2/16/2010, Vol. 14 Issue 30, p1-6, 2p
  • 34.  An Introduction to Medicinal Chemistry by Graham L. Patrick, pp. 589-590. Abbott, Alison. Neuroscience: The plaque plan. Nature (London, United Kingdom) (2008), 456(7219), 161-164. Bolognesi, Maria L.; Matera, Riccardo; Minarini, Anna; Rosini, Michela; Melchiorre, Carlo. Alzheimers disease: new approaches to drug discovery. Current Opinion in Chemical Biology (2009), 13(3), 303-308.
  • 35.  What are the three stages of Alzheimer’s Disease? What are some of the diagnostic tools of diagnosing Alzheimer’s Disease? What drugs are used to treat mild/moderate Alzheimer’s Disease? Which drug is most commonly used to treat Alzheimer’s Disease? Have current pharmaceutical agents been successful in slowing the progress of Alzheimer’s Disease? Why is it important to develop ‘biomarkers’ for Alzheimer’s Disease?

×